Klaria Pharma Holding AB (publ) receives 24.5 MSEK through directed new issue

As previously communicated on October 14, 2020, the Board of Directors of Klaria Pharma Holding AB (publ) (“Klaria” or “the Company”) resolved on a directed new issue of a maximum of 4,239,766 shares with a subscription price of SEK 6.84 per share, which corresponds to a gross payment of a maximum of approximately SEK 29 million (the “Share Issue”). The Board's resolution was approved at the Extraordinary General Meeting of the Company on November 2, 2020. Klaria hereby announces that the company has now received approximately SEK 24.5 million through the Share Issue and that 3 581 871 shares have been subscribed for.

For further information on the transaction, please see the press release on the Board's resolution, which was published on 14 October 2020.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.